Repertoire Tests Novel Cancer Therapy Targeting Multiple Tumors

CAMBRIDGE, Mass. – April 23, 2026 – Repertoire Immune Medicines, a biotechnology firm backed by Flagship Pioneering, has officially entered the clinical arena with its lead oncology candidate. The company announced today that the first patient has been dosed in a Phase 1/2 clinical trial for RPTR-1-201, a novel immune therapy designed to combat advanced solid tumors.

This milestone is not just a step forward for a single drug but also the first major clinical test of Repertoire's proprietary DECODE™ platform, an advanced system designed to decipher the complex language of the human immune system and translate it into programmable medicines. The trial, now underway in the United States and Europe, will evaluate the safety and efficacy of RPTR-1-201 both as a standalone treatment and in combination with an established anti-PD-1 checkpoint inhibitor.

A New Weapon Against Hard-to-Treat Cancers

For countless patients diagnosed with metastatic or unresectable solid tumors, the road ahead is often marked by limited and frequently ineffective treatment options. While immunotherapies have revolutionized cancer care, many tumors, often described as immunologically "cold," remain stubbornly resistant to treatment. Repertoire's RPTR-1-201 aims to change that paradigm by harnessing the power of a patient's own immune system in a highly targeted manner.

The therapy is a T cell receptor (TCR) bispecific molecule. One arm of the molecule is an engineered TCR that binds with high precision to a specific cancer marker, or epitope. The other arm, an anti-CD3 moiety, acts like a grappling hook, engaging the patient's T cells and redirecting them to find and destroy the tumor cells.

"T cell-targeted immune medicines have shown they can drive deep and durable responses in some cancers, yet many patients with advanced solid tumors still have limited treatment options," said Robert Andtbacka, MD, CM, Chief Medical Officer of Repertoire. "RPTR-1-201 is designed to direct a patient's own T cells toward a shared, tumor-selective target. Dosing the first participant is a major milestone for Repertoire and the start of evaluating RPTR-1-201's safety and potential benefit in the clinic."

What sets RPTR-1-201 apart is its target. Instead of focusing on a well-known antigen specific to a single cancer type, it binds to a novel epitope that is shared across multiple solid tumors. This discovery, made possible by the company's DECODE platform, means the therapy could potentially be relevant for up to 200,000 patients annually in the U.S. and Europe, a significant population facing dire prognoses. Preclinical studies have shown the drug's ability to kill both "hot" and "cold" tumors, suggesting it could overcome a key hurdle that limits the effectiveness of current immunotherapies.

The Power of the DECODE Platform

The initiation of this trial represents a critical validation for Repertoire's foundational technology, the DECODE platform. This sophisticated system integrates artificial intelligence with deep biological mapping to comprehensively analyze the "immune synapse"—the precise point of interaction where a T cell recognizes a cancer or pathogen-infected cell. By decoding these interactions on a massive scale, the platform aims to identify the most potent TCR-antigen pairs that can be engineered into new medicines.

"The development of RPTR-1-201 was enabled by our platform, which identified unique TCRs against a pan-tumor, tumor-selective epitope," explained Anthony J. Coyle, PhD, President, Research and Development at Repertoire. "The initiation of this trial marks an important milestone, as RPTR-1-201 is the first validation of our ability to convert immune codes into potential immune medicines for cancer."

This clinical progress follows a strategic pivot for the company. In late 2022, Repertoire shifted its focus away from earlier cell-based therapies that showed modest results, choosing instead to concentrate on developing scalable, "off-the-shelf" medicines like TCR bispecifics. This decision appears to be bearing fruit, not only with the advancement of RPTR-1-201 but also by attracting significant interest from major pharmaceutical partners. The company has since inked high-value collaboration deals with Bristol Myers Squibb, Genentech, and Eli Lilly, primarily focused on applying the DECODE platform to autoimmune diseases, which has infused the company with capital and provided powerful external validation of its technology.

Navigating a Competitive Immuno-Oncology Landscape

Repertoire enters a dynamic and fiercely competitive field. The race to successfully apply T-cell engaging therapies to solid tumors is one of the most active areas in oncology research. While CAR-T cell therapies have achieved remarkable success in blood cancers, their application in solid tumors has been hampered by challenges including tumor heterogeneity, the immunosuppressive tumor microenvironment, and complex, costly manufacturing processes.

Recent FDA approvals, such as Iovance Biotherapeutics' lifileucel for advanced melanoma and Adaptimmune's afami-cel for synovial sarcoma, have proven that cell therapies can break through in the solid tumor space. However, these are autologous therapies, requiring a patient's own cells to be extracted and engineered.

Repertoire’s RPTR-1-201 represents a different approach. As an off-the-shelf bispecific, it can be manufactured at scale and administered more readily, avoiding the logistical hurdles of personalized cell therapies. Its key differentiator lies in its target—a novel, shared antigen—which could give it a broader utility than therapies aimed at single-tumor antigens. The ability to work in "cold" tumors, if proven in humans, would be another significant advantage over existing checkpoint inhibitors that rely on a pre-existing immune response.

Clinical Pathway and Future Outlook

The Phase 1/2 trial for RPTR-1-201, identified as NCT07293754 and named RaPTR-101, is meticulously designed to answer critical questions about the drug's potential. The initial dose-escalation phase will focus on establishing a safe and tolerable dose. This will be followed by a dose-expansion phase to gather preliminary data on its anti-tumor activity in specific cancer types.

Crucially, the study will evaluate RPTR-1-201 both as a monotherapy and in combination with an anti-PD-1 therapy. This combination strategy is vital, as combining a T-cell engager with a checkpoint inhibitor could create a powerful synergistic effect, unleashing T cells while simultaneously removing the brakes that tumors put on the immune system. The trial's primary completion is estimated for late 2028, with full results anticipated in 2029.

With substantial funding from a $189 million Series B round and a string of lucrative partnerships with pharmaceutical giants, including a prostate cancer collaboration with Pfizer, Repertoire is well-positioned to see its lead program through these early clinical stages. The journey for RPTR-1-201 is just beginning, but for patients with advanced solid cancers, it represents a new and promising front in the ongoing fight.